Business Wire

AURAK

15.12.2018 11:51:08 CET | Business Wire | Press release

Share
AURAK Gains SACSCOC Accreditation

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/

SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now joins the very small group of elite international higher education institutions that have attained SACSCOC accreditation and can enjoy the diverse benefits of membership in this highly revered organization.

“Accreditation by SACSCOC signifies that the institution has a mission appropriate to higher education, has resources, programs, and services sufficient to accomplish and sustain that mission, and maintains clearly specified educational objectives that are consistent with its mission and appropriate to the degrees its offers, and that indicate whether it is successful in achieving its stated objectives.”

“The culmination of the accreditation process is a public statement of an institution’s continuing capacity to provide effective programs and services based on agreed-upon requirements. The statement of an institution’s accreditation status with SACSCOC also represents an affirmation of an institution’s continuing commitment to the Commission’s principles and philosophy of accreditation.”

AURAK is a nonprofit, government-owned institution of higher education which provides the local, regional and international communities with a North American-style education integrated with Arabic customs and traditions. It is licensed by the Ministry of Education in the UAE and offers a total of 22 accredited undergraduate and graduate programs across a wide range of disciplines. Despite having this primary local accreditation, AURAK was determined to broaden its impact in higher education by obtaining internationally recognized institutional and program accreditations. To date, the institution has six programs accredited by the Accreditation Board for Engineering and Technology (ABET) and institutional accreditation by SACSCOC. It should be noted that in the case of institutional accreditation by SACSCOC, an institution is also expected to document and demonstrate the quality and effectiveness of all its programs and services although the agency does not award individual program accreditation.

AURAK has been working diligently towards obtaining SACSCOC accreditation since 2014 and successfully achieved candidacy status in July of 2017. This paved the way for the institution to undergo even more rigorous and comprehensive onsite review by a SACSCOC Accreditation Committee. The Committee found the institution to be in compliance with all accreditation standards and requirements. Further internal reviews were conducted by SACSCOC in keeping with its multi-tiered peer review process, the culmination of which was AURAK obtaining SACSCOC accreditation.

This was a formidable achievement that was four years in the making. It demonstrates the tenacity, determination and commitment of AURAK to achieving excellence in all its undertakings – for its students, faculty, staff and other stakeholders.

“The long- standing dream and goal has come true in a record time. The report is positive and clear.” Professor Hassan beamed proudly during the declaration of AURAK’s SACSCOC accreditation status. “Today AURAK is among the first universities in the Middle East and North Africa (MENA) region to successfully initiate and complete the entire accreditation process as an applicant institution to secure membership from the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), affirming that AURAK is not only as an institution of quality among Arabic educational institutions, but also on an international level as well. This accreditation validates our claims of providing students with a highly rigorous curriculum from the credentialed and highly knowledgeable faculty we have always strived to hire and support. AURAK has achieved in a very short time what some other institutions have failed to do in decades.

I would like to seize this opportunity to thank the AURAK family and supporters for their loyalty, dedication, and hard work. Without them, AURAK would not be the exemplar of educational excellence it is. Today our aspirations and our hard work have been realized. In gaining SACSCOC membership we join a community of highly respected institutions. We look forward to offering a vast array of educational opportunities through which we will continue to develop and excel.”

*Source: AETOSWire

Contact:

American University of Ras Al Khaimah Helen Amhani , Manager, Department of Communications and Public Relations +97172210900 Ext: 1445 hamhani@aurak.ac.ae

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye